Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (NCT06223958)

🧪 Interventions in This Study

• OTX-TKI (axitinib implant) (DRUG)
• Aflibercept (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (108 Sites)

Showing the first 25 of 108 sites.

• Associated Retina Consultants - Gilbert — Gilbert, Arizona
• Associated Retina Consultants - Phoenix — Phoenix, Arizona
• Retinal Research Institute — Phoenix, Arizona
• Retina Macula Institute of Arizona — Scottsdale, Arizona
• CA CRC California Retina Consultants — Bakersfield, California
• The Retina Partners - Encino — Encino, California
• Retina Consultants of Orange County - Fullerton — Fullerton, California
• Atlantis Eyecare — Huntington Beach, California
• Lakeside Vision Center - Irvine — Irvine, California
• Retina-Vitreous Associates Medical Group - Los Angeles — Los Angeles, California
• CA RCMG Retinal Consultants Medical Group, Inc. — Modesto, California
• Retina Sacramento MSO, LLC — Modesto, California
• Kaiser Permanente Division of Research — Oakland, California
• CA CRC California Retina Consultants — Oxnard, California
• Stanford University School of Medicine, Byers Eye Institute — Palo Alto, California
• Doheny Eye Center — Pasadena, California
• AzulVision — Pasadena, California
• Orange County Retina Medical Group — Santa Ana, California
• California Retina Consultants (CRC) - Santa Barbara — Santa Barbara, California
• Macula Retina Vitreous Center — Torrance, California
• Bay Area Retina Associates, A Medical Group — Walnut Creek, California
• Retina Consultants of Southern Colorado - Colorado Springs — Colorado Springs, Colorado
• RSC Research, PLLC — Denver, Colorado
• Colorado Retina Associates (CRA) - Lakewood — Lakewood, Colorado
• Retina Group of New England, PC — Waterford, Connecticut

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neovascular Age-Related Macular Degeneration

• A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Arcadia, California
• A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
• Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) — Beverly Hills, California
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Gilbert, Arizona
• Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD — Glendale, California
• Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] — Phoenix, Arizona

Explore by condition: All Neovascular Age-Related Macular Degeneration clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.